This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Roche's Acquisition of Genentech
Baldwin, Carliss Y.; Becker, Bo; Dessain, VincentCase HBS-210040-EFinanceFranz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, tStarting at €8.20
-
The Novartis Malaria Initiative
Chu, Michael; Dessain, Vincent; Billaud, EmilieCase HBS-314103-EBusiness Ethics and Corporate Social ResponsibilityThe Novartis Malaria Initiative was designed, as a result of a precedent-setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria-"at no profit"-for public health systems. What had begun as an exemplary act of corporate responsibility had succeeded beyond any expectations. In 2012, for the second year in a row, Novartis had manufactured and distributed over 100 million units of the anti-malaria...Starting at €8.20
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Ilva Steel Taranto: Providing and Polluting (C)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCase HBS-314059-EStarting at €5.74
-
BASF: Co-Creating Innovation (B)
Rangan, V. Kasturi; Billaud, Emilie; Dessain, VincentCase HBS-517074-EMarketingSupplement to case 517073.Starting at €5.74
-
Poles apart on PZU (C)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCase HBS-912015-EAfter a decade-long dispute with the Polish State Treasury, in October 2009 the Dutch insurer Eureko agreed to exit PZU in exchange for compensation. Who was the biggest beneficiary of the settlement: Eureko, the Treasury, or PZU itself?Starting at €5.74
-
Ilva Steel Taranto: Providing and Polluting (B)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCase HBS-314058-EStarting at €5.74
-
Veolia: Resourcing the World
Ahuja, Gautam; Khanna, Tarun; Maslauskaite, Kristina; Dessain, VincentCase HBS-717505-EStrategyA global environmental service provider goes through major changes to offer integrated solutions and reach out to new countries.Starting at €8.20
-
Poles apart on PZU (B)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCase HBS-912014-EIn September 2008, the Polish State Treasury and the Dutch insurer Eureko were wondering if they were ready for reaching an amicable solution on PZU. If so, for how much and under what conditions should they settle so that they, as well as PZU, are satisfied? If not, what other potential alternatives might exist?Starting at €5.74